The story of VÖOST is not one of clinical trials or digital therapeutics, but of a simple, fizzy tablet meeting a generational shift in wellness. Founded in 2013, the Australian brand carved out a 35% share of the country's effervescent vitamin market within three years by targeting a demographic often overlooked by traditional supplement aisles: Millennial and Gen-Z consumers [SmartCompany, July 2016]. It was a bet on format, flavor, and marketing savvy over clinical potency, a consumer packaged goods play in the often-serious world of health.
The brand's trajectory, culminating in a 2021 acquisition by Procter & Gamble, offers a clear case study in how to wedge into a mature market. By 2016, the company reported approximately $5 million in brand value and had built its presence to nearly 3,000 stockists across Australia, from pharmacies to supermarkets [SmartCompany, July 2016][SmartCompany, April 2021]. For Pulse Raman, who typically reports on molecules and algorithms seeking FDA approval, VÖOST serves as a reminder that patient adoption often starts long before a prescription, in the daily habits shaped by taste, convenience, and brand trust.
The Wedge Was Flavor and Format
VÖOST's founders, including former Coles executive Thomas Siebel, identified a gap. The Australian vitamin market was dominated by pills, capsules, and powders often marketed with clinical or athletic imagery. Their insight was that a growing cohort of younger consumers approached wellness as a daily, accessible ritual, not a medical intervention. The effervescent tablet,dropped into water to create a flavored, fizzy drink,was the perfect vehicle. It was positioned as a "better for you" product, free from artificial colors, preservatives, and flavors, but its primary appeal was experience over efficacy [LinkedIn, Steven Ivak, accessed 2026][SmartCompany, July 2016].
The company claimed to offer the widest range of effervescent vitamins in Australia, turning a niche format into a broad product line [Facebook, Unknown]. This allowed for segmentation within their target audience: vitamin C for immunity, B vitamins for energy, magnesium for recovery. The strategy was less about treating a deficiency and more about integrating a branded, pleasant moment into a consumer's daily routine.
A Foundational Team From CPG, Not Biotech
The founding team's background explains the commercial, rather than scientific, focus of the venture. Thomas Siebel brought experience from the fast-moving consumer goods (FMCG) world as a former managing director for Sakata rice crackers [SmartCompany, July 2016]. Co-founders Jason Scher, Rudi van der Vlies, and Stuart Lawson were also long-term business partners with backgrounds in brand building and operations [LinkedIn, Rudi van der Vlies, accessed 2026]. This was a group skilled in logistics, retail distribution, and consumer marketing.
Their collective experience is summarized in the table below, highlighting the commercial DNA that defined VÖOST's path.
| Founder | Role | Relevant Background |
|---|---|---|
| Thomas Siebel | Co-founder, Managing Director | Former MD of Sakata rice crackers; FMCG executive [SmartCompany, July 2016]. |
| Jason Scher | Co-founder | Current ANZ head of Kruger coffee pods; brand and sales leadership [Business News Australia, Unknown]. |
| Rudi van der Vlies | Co-founder | Long-term business partner of Scher and Lawson [LinkedIn, Rudi van der Vlies, accessed 2026]. |
| Stuart Lawson | Co-founder | Long-term business partner of Scher and van der Vlies [LinkedIn, Rudi van der Vlies, accessed 2026]. |
Scaling Through Physical Retail
Unlike many modern DTC brands that begin online, VÖOST's growth was anchored in physical retail distribution. The nearly 3,000 stockists figure by 2016 is a testament to a classic, grind-it-out sales strategy [SmartCompany, April 2021]. Securing shelf space in major pharmacy chains and supermarkets gave the brand mass-market visibility and impulse-purchase appeal. While the brand was described as a digitally marketed alternative, its foundation was a ubiquitous physical presence, making the vitamins an easy, accessible choice for a broad audience.
This asset,a dense retail network,likely formed a key part of the acquisition thesis for Procter & Gamble in 2021. For a global CPG giant, VÖOST represented a ready-made, leading brand in a specific wellness category with deep in-store relationships [Australian Financial Review, April 2021]. The acquisition price was not disclosed, but the exit validated the founders' bet on a specific format and demographic.
The Limits of a CPG Approach to Health
For all its commercial success, VÖOST's story also highlights the natural limits of a purely consumer-brand approach to health. The brand's claims rested on general wellness, not on treating a specific, diagnosed condition. There is no public record of clinical studies to substantiate bioavailability or efficacy advantages of their effervescent formulations compared to other formats. In a regulatory context, these products operate in the supplements space, which has different evidence requirements than therapeutic goods.
The competitive moat, therefore, was brand affinity and distribution, not scientific IP. This made the company an attractive acquisition for a company like P&G, but it also defines the arena in which it operated. It was competing with other consumer brands like Berocca, not with pharmaceutical companies. The risks were commercial,shifts in consumer taste, private-label competition, retail margin pressure,not clinical or regulatory.
What the Exit Means for the Category
The Procter & Gamble acquisition signals that large, traditional CPG companies see sustained value in the everyday wellness category, particularly when it connects with younger consumers. For startups in the adjacent space of digital health or clinical nutrition, VÖOST's journey is a parallel lesson in consumer adoption. Even the most sophisticated therapeutic intervention must eventually navigate the final mile of patient habit and preference.
For the millions of generally healthy adults and younger consumers who take a daily vitamin, the standard of care is often a self-selected over-the-counter product bought off a retail shelf. The decision is influenced by taste, convenience, brand messaging, and price,the very levers VÖOST mastered. Their success in capturing a third of the Australian effervescent market shows that in the vast landscape of health, there is significant territory between the pharmacy and the clinic, waiting for the right product-market fit.
Sources
- [SmartCompany, July 2016] How ex-supermarket boss Tom Siebel is taking the Australian vitamin market by storm with $5 million brand VÖOST | https://www.smartcompany.com.au/entrepreneurs/how-ex-supermarket-boss-tom-siebel-is-taking-the-australian-vitamin-market-by-storm-with-5-million-brand-voost/
- [SmartCompany, April 2021] Dusty’s goalkicking helps power Voost buyout | https://www.afr.com/companies/healthcare-and-fitness/voost-vitamins-bought-by-procter-and-gamble-20210412-p57iea
- [William Hood & Company, accessed 2026] William Hood & Company case study | https://www.williamhoodandcompany.com/case-study/voost
- [LinkedIn, Steven Ivak, accessed 2026] LinkedIn profile referencing product development | https://www.linkedin.com/in/steven-ivak
- [Facebook, Unknown] VÖOST Vitamins Facebook page | https://www.facebook.com/dailyVOOST/
- [Business News Australia, Unknown] Vitamins brand VOOST acquired by Procter & Gamble | https://www.businessnewsaustralia.com/articles/supplements-brand-voost-acquired-by-procter---gamble.html
- [LinkedIn, Rudi van der Vlies, accessed 2026] LinkedIn profile showing co-founder relationships | https://www.linkedin.com/in/rudi-van-der-vlies-25008529/
- [Australian Financial Review, April 2021] Voost vitamins bought by Procter and Gamble | https://www.afr.com/companies/healthcare-and-fitness/voost-vitamins-bought-by-procter-and-gamble-20210412-p57iea